Medcura
Series B Equity Offering
Medcura presents a compelling investment opportunity in the rapidly growing global hemostasis market, which is ripe for technological disruption. The company has developed a novel biopolymer platform that has received the first and only FDA Breakthrough Device Designation for a surgical hemostat, addressing the critical need for non-swelling solutions in delicate surgical procedures. Medcura’s flagship product, LifeGel, is poised to revolutionize the $2.8 billion global hemostasis market by offering a unique combination of high safety, efficacy, and cost-effectiveness.
COMPANY HIGHLIGHTS:
o Market Opportunity: Medcura’s portfolio targets approximately 85% of the $2.8 billion global hemostasis market, with a particular focus on the $600 million global spine hemostasis segment
o Innovative Technology: Proprietary biopolymer platform leverages advanced chemistry to create customized performance, addressing longstanding issues such as swelling and high costs
o Regulatory Progress: Five 510(k) clearances and two FDA Breakthrough Device Designations demonstrate differentiation, regulatory de-risking and potential for accelerated approval pathways
o Margin Potential: With substantially lower cost of goods, LifeGel offers significantly higher profitability compared to thrombin-based competitors’ margins
o Intellectual Property: Extensive patent protection in the U.S. and EU, coupled with years of product design and process know-how, creates significant barriers to entry
o Experienced Management: Accomplished team with a track record of successful product development, regulatory approvals and large exits in the medical device industry
o Financial Projections: Medcura projects LifeGel launching in 2027, growing from $14 million in Year 1 to $90 million by Year 3 and $200 million in Year 5, driven by adoption in both ambulatory spinal surgery centers & hospitals. These forecasts do not include upside use of LifeGel elsewhere in surgery or revenues from other platform form factors
o Exit Potential: The surgical hemostasis space has seen consistent M&A activity as acquisitions are a key strategy for incumbents to defend market dominance and expand product lines
